Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo

Abstract

Background: It has been argued that measurement of outcome in panic disorder should not be limited to monitoring the number of panic attacks, but should include all domains that affect patient quality of life.

Methods: Data from a randomized prospective comparison of escitalopram, citalopram, and placebo in patients with DSM-IV panic disorder were analyzed with regard to measurements of impairment of quality of life. The subscales of the Panic and Agoraphobia Scale (P&A) (Panic Attacks, Agoraphobic Avoidance, Anticipatory Anxiety, Functional and Social Disability, and Worries about Health) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were analyzed.

Results: Treatment with escitalopram was associated with significant improvement on all 5 subscales of the P&A. Citalopram was significantly different from placebo in 3 subscales. Escitalopram and citalopram were significantly better than placebo in improving quality of life (measured by the total score of the Q-LES-Q Scale). Escitalopram was superior to placebo on 12 of 16 items of the Q-LES-Q, while citalopram was superior on 7 items.

Conclusion: The P&A scale was more robust than measurement of panic frequency in differentiating medication from placebo. Escitalopram treatment was associated with improvement on all assessed domains that impair quality of life in panic disorder. Measurement of clinical improvement should not be solely based on panic attack frequency, but should also include assessment of a broad range of domains that affect patient quality of life.

References

• 1 APA. American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. >Fourth Edition Washington DC: American Psychiatric Press 1994
• 2 Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis.  International Journal of Psychiatry in Clinical Practice. 2003;  7 259-268
• 3 Baldwin DS, Anderson IM, Nutt DJ. et al . Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.  J Psychopharmacol. 2005;  19 567-596
• 4 Bandelow B. Panic and Agoraphobia Scale (PAS). Göttingen, Bern, Toronto, Seattle: Hogrefe & Huber Publishers 1999
• 5 Bandelow B. Epidemiology of Depression and Anxiety. In: Kasper S, den Boer JA, Sitsen AJM (editors) Handbook on Depression and Anxiety. New York, NY: M. Dekker 2003: 49-68
• 6 Bandelow B, Amering M, Benkert O. et al . Cardio-respiratory and other symptom clusters in panic disorder.  Anxiety. 1996;  2 99-101
• 7 Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression.  Depress Anxiety. 2007;  24 53-61
• 8 Bandelow B, Broocks A, Pekrun G. et al . The use of the Panic and Agoraphobia Scale (P&A) in a controlled clinical trial.  Pharmacopsychiatry. 2000;  33 174-181
• 9 Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?.  J Clin Psychiatry. 2006;  67 1428-1434
• 10 Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Rüther E. Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems.  Int Clin Psychopharmacol. 1995;  10 83-93
• 11 Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders.  World J Biol Psychiatry. 2002;  3 171-199
• 12 Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.  Pharmacopsychiatry. 2006;  39 128-134
• 13 Boulenger JP, Huusom AKT, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severe major depression.  Curr Opin Med Res. 2006;  22 1331-1341
• 14 Candilis PJ, MacLean RY, Otto MW. et al . Quality of life in patients with panic disorder.  J Nerv Ment Dis. 1999;  187 429-434
• 15 Diamond R, Becker M. The Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life.  J Clin Psychiatry. 1999;  60 ((Suppl 3)) 29-31
• 16 EMEA. European Medicines Agency . Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Panic Disorder http://www.emea.europa.eu/pdfs/human/ewp/428002en.pdf. , Last accessed 3 May 2007; 
• 17 Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.  Psychopharmacol Bull. 1993;  29 321-326
• 18 Frisch MB, Clark MP, Rouse SV. et al . Predictive and treatment validity of life satisfaction and the quality of life inventory.  Assessment. 2005;  12 66-78
• 19 Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.  CNS Spectr. 2002;  7 40-44
• 20 Guy W. Clinical Global Impression Scale (CGI) .ECDEU Assessment Manual for Psychopharmacology. In Washington, DC: National Institute of Mental Health-US Dept of Health, Education, and Welfare publication (ADM) 1976: 76-338
• 21 Hamilton M. The assessment of anxiety states by rating.  Br J Med Psychol. 1959;  32 50-55
• 22 Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.  Pharmacopsychiatry. 2006;  39 180-184
• 23 Leucht S, Kane JM, Etschel E, Kissling W, Hamann JRR. Linking the PANSS, BPRS, and CGI: clinical implications.  Neuropsychopharmacology. 2006;  31 2318-2325
• 24 Lochner C, Mogotsi M, Toit PL du. et al . Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder.  Psychopathology. 2003;  36 255-262
• 25 Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders.  Am J Psychiatry. 2000;  157 669-682
• 26 Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.  Int Clin Psychopharmacol. 2005;  20 131-137
• 27 Quilty LC, Ameringen M Van, Mancini C, Oakman J, Farvolden P. Quality of life and the anxiety disorders.  J Anxiety Disord. 2003;  17 405-426
• 28 Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders.  Am J Psychiatry. 2005;  162 1171-1178
• 29 Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C. Is placebo response the same as drug response in panic disorder?.  Am J Psychiatry. 2000;  157 1014-1016
• 30 Sánchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer.  Psychopharmacology (Berl). 2004;  174 163-176
• 31 Shear MK, Brown TA, Barlow DH. et al . Multicenter collaborative panic disorder severity scale.  Am J Psychiatry. 1997;  154 1571-1575
• 32 Simon NM, Otto MW, Korbly NB. et al . Quality of life in social anxiety disorder compared with panic disorder and the general population.  Psychiatr Serv. 2002;  53 714-718
• 33 Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.  J Clin Psychiatry. 2003;  64 1322-1327
• 34 Stewart AL, Hays RD, Ware  Jr  JE. The MOS short-form general health survey. Reliability and validity in a patient population.  Medical care. 1988;  26 724-735

Correspondence